Beverly Hills, California (PRWEB) November 17, 2014

Veteran television and movie actor Darius McCrary has received a revolutionary stem cell procedure for his painful knee and ankle. The regenerative medicine procedure with stem cells was performed by Dr. Raj, a top orthopedic doctor in Beverly Hills and Los Angeles.

Darius McCrary is well known for his decade long stint on Family Matters as character Eddie Winslow. He won a Best Young Actor Award for this role along with movie roles in both Mississippi Burning and Big Shots. Currently, Darius appears along with Charlie Sheen in the show Anger Management.

While staying in tip top shape for his career, Darius has developed persistent pain in his right knee and ankle. Rather than seek a regular cortisone injection for pain relief or opt for surgery, he desired the ability to repair the joint damage and achieve pain relief. "I couldn't imagine being immobilized because of injury, so I opted for a stem cell procedure."

The procedures were performed by Dr. Raj, who is a prominent Beverly Hills orthopedic doctor with extensive experience in regenerative medicine. The procedure consisted of a combination of platelet rich plasma therapy along with amniotic derived stem cell therapy. Anecdotal studies are showing that the stem cell procedures for extremity joints allow patients to achieve pain relief and often avoid the need for potentially risky surgery.

Dr. Raj has performed over 100 stem cell procedures for patients who have degenerative arthritis or sports injuries. "Patients do extremely well with the procedures. Minimal risk and there's a huge potential upside!"

With an active acting career, Darius McCrary cannot afford to be distracted with chronic pain. "I'm looking forward to getting back in the gym and going hard without this pain," he stated excitedly. The procedure was filmed and can be seen on Dr. Raj's Facebook page.

To discuss stem cell procedures at Beverly Hills Orthopedic Institute and how they can benefit, call (310) 247-0466.

Here is the original post:

Veteran Actor Darius McCrary from Family Matters Receives Stem Cell Procedures with Dr. Raj in Beverly Hills

Lumbar Disc Stem Cell Therapy Request for Funding

By: Connor Malander

Excerpt from:

Lumbar Disc Stem Cell Therapy Request for Funding - Video

Why Stem Cells Aren #39;t Being Tested in the US
Stem cell treatment is restricted in the United States, and we discuss the reasons the FDA has been so restrictive about the game-changing research and thera...

By: TheLipTV

Read more here:

Why Stem Cells Aren't Being Tested in the US - Video

Dr Saw Khay Yong Stem Cell Therapy for the Musculoskeletal System

By: Admin KLSMC

Read more from the original source:

Dr Saw Khay Yong Stem Cell Therapy for the Musculoskeletal System - Video

4 hours ago

New research in flies shows how cells in adult reproductive organs maintain their sexual identity. The study, publishing online on November 13 in the Cell Press journal Developmental Cell, also identified a mutation that can switch the cells' sexual identity. The findings could lead to new insights on how to alter cells for therapeutic purposes.

Sperm and eggs are made from germ cells, but instructions from their neighboring support cellscalled somatic cellsare also essential for their development. By studying the formation of sperm in fruit flies, which is remarkably similar to the process that occurs in people, investigators serendipitously found a mutation that gave testes a very unusual appearance. "Rather than becoming sperm, germ cells were stuck at an early stage, and they were surrounded by support cells that looked suspiciously like those belonging in an ovary," says senior author Dr. Erika Matunis of The Johns Hopkins School of Medicine. Her research team found that the mutation blocked the function of a specific gene in the stem cells that becomes support cells in the testis, causing the fruit flies to change from a male to a female identity.

The research is the first to show that adult stem cells actively maintain their sexual identity. The mutation the investigators found causes the stem cells in males to switch their sexual identities and start making support cells that belong in the ovary. This ultimately derails the production of sperm. "The molecules that govern this process are highly conserved, which suggests that similar mechanisms could operate in human testes," says Matunis.

The changes seen in this study are an example of transdifferentiation, or the conversion from one cell type to another. The topic is of considerable interest because promoting transdifferentiation in a directed manner may be useful for regenerating damaged organs or tissues. Doing so will require a thorough understanding of how cell fate conversions are regulated. "We are excited to have a powerful genetic system for studying transdifferentiation of stem cells at the mechanistic level," says Matunis. The research might also provide insights into how cells transform from a normal state to a cancerous one.

Explore further: Surprise: Lost stem cells naturally replaced by non-stem cells, fly research suggests

More information: Developmental Cell, Ma et al.: "The Jak-STAT target Chinmo prevents sex transformation of adult stem cells in the Drosophila testis niche" http://www.cell.com/developmental-cel 1534-5807(14)00628-5

Journal reference: Developmental Cell

Provided by Cell Press

Johns Hopkins researchers have discovered an unexpected phenomenon in the organs that produce sperm in fruit flies: When a certain kind of stem cell is killed off experimentally, another group of non-stem cells can come out ...

Read more:

How adult fly testes keep from changing into ovaries

Magnifisio dashed home strongly over 1400m to win Saturdays Lee-Steere Stakes at Ascot. Picture: Westernracepix

Sprinter Smoko will have stem cell therapy at Murdoch Veterinary Hospital to a strained suspensory ligament in his off-foreleg.

Vets found Smoko had strained the ligament when he pulled up sore following his shock sixth as a $2 favourite to Shining Knight in last Tuesday's Colonel Reeves Stakes (1100m) at Ascot.

Co-trainer Ross Price said Smoko would be sidelined for months.

"He will go to Murdoch where they will look at him and see about stem cell therapy," he said.

"In about 10 days we will take him up there and see what they can do. It is then going to be five months off and hoping."

Smoko was a $6.50 chance in Saturday week's Winterbottom Stakes (1200m) before he was scratched. WA's hopes of winning back the Group 1 weight-for-age hinge on Magnifisio, Shining Knight and Testamezzo, with Barakey in doubt after struggling to recover from a virus.

"He is still feeling flat and I will have to wait and see if he improves over the next few days," trainer Jim Taylor said.

Magnifisio firmed from $12 into $8 on the TAB yesterday following her strong win at her debut over 1400m in Saturday's Group 2 Lee-Steere Stakes at Ascot.

Melbourne sprinters Angelic Light, Moment Of Change and reigning champion Buffering dominate betting at $4.30, $6.50 and $7.50.

Follow this link:

Stem cell therapy for sidelined star Smoko

PUBLIC RELEASE DATE:

10-Nov-2014

Contact: Ccile Martinat CMARTINAT@istem.fr 33-603-855-477 INSERM (Institut national de la sant et de la recherche mdicale) @inserm

This news release is available in French.

The motor neurons that innervate muscle fibres are essential for motor activity. Their degeneration in many diseases causes paralysis and often death among patients. Researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/AFM/UEVE), in collaboration with CNRS and Paris Descartes University, have recently developed a new approach to better control the differentiation of human pluripotent stem cells, and thus produce different populations of motor neurons from these cells in only 14 days. This discovery, published in Nature Biotechnology, will make it possible to expand the production process for these neurons, leading to more rapid progress in understanding diseases of the motor system, such as infantile spinal amyotrophy or amyotrophic lateral sclerosis (ALS).

Human pluripotent stem cells have the ability to give rise to every cell in the body. To understand and control their potential for differentiation in vitro is to offer unprecedented opportunities for regenerative medicine and for advancing the study of physiopathological mechanisms and the quest for therapeutic strategies. However, the development and realisation of these clinical applications is often limited by the inability to obtain specialised cells such as motor neurons from human pluripotent stem cells in an efficient and targeted manner. This inefficiency is partly due to a poor understanding of the molecular mechanisms controlling the differentiation of these cells.

Inserm researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/French Muscular Dystrophy Association [AFM]/University of vry Val d'Essonne [UEVE]), in collaboration with CNRS and Paris-Descartes University, have developed an innovative approach to study the differentiation of human stem cells and thus produce many types of cells in an optimal manner.

"The targeted differentiation of human pluripotent stem cells is often a long and rather inefficient process. This is the case when obtaining motor neurons, although these are affected in many diseases. Today, we obtain these neurons with our approach in only 14 days, nearly twice as fast as before, and with a homogeneity rarely achieved," explains Ccile Martinat, an Inserm Research Fellow at I-Stem.

To achieve this result, the researchers studied the interactions between some molecules that control embryonic development. These studies have made it possible to both better understand the mechanisms governing the generation of these neurons during development, and develop an optimal "recipe" for producing them efficiently and rapidly.

"We are now able to produce and hence study different populations of neurons affected to various degrees in diseases that cause the degeneration of motor neurons. We plan to study why some neurons are affected and why others are preserved," adds Stphane Nedelec, an Inserm researcher in Ccile Martinat's team.

Read the original:

Production of human motor neurons from stem cells is gaining speed

The day Olivia Cox was diagnosed with Type 1 diabetes at age 16, her mother vowed to find a cure.

"I said to her, "there's someone walking this Earth who has been cured of diabetes, and I'm going to find him," Ruth Cox said.

Cox's search started with a call to Harvard University and ended with a family trip to Lima, Peru. It was at a clinic there that now 18-year-old Olivia and her father, Jeff, 54, who also has diabetes, received an infusion of stem cells designed to wipe out diabetes in their bodies or, at the very least, lessen its impact. The treatment illegal in the United States cost $70,000 for both father and daughter. Two months later, the Niskayuna family is waiting for a transformation and wondering if, in their desperation for a cure, they were snookered by false promises.

Because stem cells can be programmed to become anything from heart muscle to toenails, stem cell therapy can hypothetically be used to treat anything, from baldness to Lou Gehrig's Disease. But the study of regenerative medicine is still nascent in the United States, where it is restricted to procedures that use the patient's own cells, and it has been primarily used in treating cancer a procedure that saved Ruth Cox 13 years ago, when she had breast cancer.

Stem cell treatment using donor cells is more common elsewhere in the world, but with varying results and none that could be described as a cure. An executive order from President Barack Obama opened up funding for stem cell research and there are now more than 4,000 clinical trials under way, some on animals and some recruiting people with various ailments.

The American Diabetes Association strongly supports stem cell research, according to a statement posted on its website, which reads in part:

"Scientists from across the United States and throughout the world, including those involved with the American Diabetes Association believe that stem cell research, especially embryonic stem cell research, holds great promise in the search for a cure and better treatments for diabetes."

Jeff Cox, diagnosed with Type 1 diabetes when he was 11, has suffered none of the complications that often come with the disease neuropathy, loss of vision and heart disease. But Cox said living with diabetes is hell. He pricks his finger at least a dozen times a day to check his blood sugar level, because it is a more precise reading than the glucose monitor he wears. He also wears a pump that he programs to inject him with insulin automatically based on his diet and exercise each day. All the therapies used to treat diabetes are designed to intervene where the pancreas has gone awry.

In Type 1 diabetes, the pancreas doesn't produce insulin due to an autoimmune attack against the beta cell that produces insulin the hormone that converts glucose into energy our bodies need to survive. The Coxes didn't want their daughter to face a lifetime of managing her diabetes. They wanted a cure, and they were willing to take a risk to find it.

In order to treat diabetes with stem cell therapy, pancreatic stem cells isolated from umbilical cord blood that are programmed to produce insulin, plus autologous mesenchymal stem cells from the patient's bone marrow, are injected. Once in the pancreas, the cells are supposed to replicate themselves, gradually replacing the non-insulin producing cells in the host's pancreas. The treatment is conducted in Peru, China, Russia and India and elsewhere, but Zubin Master, a bioethicist at Albany Medical College, said the risks of traveling abroad for stem cell therapy range from paying for an expensive treatment that doesn't work, to cancer and death.

See original here:

Family's desperate bet on a diabetes cure

4 hours ago Neurons (green) are detected by TuJI whereas motoneurons are revealed in red by the visicular transporter of acetylcholine. Credit: Inserm/Martinat, Ccile

The motor neurons that innervate muscle fibres are essential for motor activity. Their degeneration in many diseases causes paralysis and often death among patients. Researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/AFM/UEVE), in collaboration with CNRS and Paris Descartes University, have recently developed a new approach to better control the differentiation of human pluripotent stem cells, and thus produce different populations of motor neurons from these cells in only 14 days. This discovery, published in Nature Biotechnology, will make it possible to expand the production process for these neurons, leading to more rapid progress in understanding diseases of the motor system, such as infantile spinal amyotrophy or amyotrophic lateral sclerosis (ALS).

Human pluripotent stem cells have the ability to give rise to every cell in the body. To understand and control their potential for differentiation in vitro is to offer unprecedented opportunities for regenerative medicine and for advancing the study of physiopathological mechanisms and the quest for therapeutic strategies. However, the development and realisation of these clinical applications is often limited by the inability to obtain specialised cells such as motor neurons from human pluripotent stem cells in an efficient and targeted manner. This inefficiency is partly due to a poor understanding of the molecular mechanisms controlling the differentiation of these cells.

Inserm researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/French Muscular Dystrophy Association [AFM]/University of vry Val d'Essonne [UEVE]), in collaboration with CNRS and Paris-Descartes University, have developed an innovative approach to study the differentiation of human stem cells and thus produce many types of cells in an optimal manner.

"The targeted differentiation of human pluripotent stem cells is often a long and rather inefficient process. This is the case when obtaining motor neurons, although these are affected in many diseases. Today, we obtain these neurons with our approach in only 14 days, nearly twice as fast as before, and with a homogeneity rarely achieved," explains Ccile Martinat, an Inserm Research Fellow at I-Stem.

To achieve this result, the researchers studied the interactions between some molecules that control embryonic development. These studies have made it possible to both better understand the mechanisms governing the generation of these neurons during development, and develop an optimal "recipe" for producing them efficiently and rapidly.

"We are now able to produce and hence study different populations of neurons affected to various degrees in diseases that cause the degeneration of motor neurons. We plan to study why some neurons are affected and why others are preserved," adds Stphane Nedelec, an Inserm researcher in Ccile Martinat's team.

In the medium term, the approach should contribute to the development of treatments for paralytic diseases such as infantile spinal muscular amyotrophy or amyotrophic lateral sclerosis. "Rapid access to large quantities of neurons will be useful for testing a significant number of pharmacological drugs in order to identify those capable of preventing the death of motor neurons," concludes Ccile Martinat.

Explore further: Team finds a better way to grow motor neurons from stem cells

More information: Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes, Nature Biotechnology, 17 Nov 2014. DOI: 10.1038/nbt.3049

See the original post:

Production of human motor neurons from stem cells gaining speed

Stem Cell Research Therapy Explained - From MS to Spinal Injury
Stem cell treatment and research towards curing illness--from multiple sclerosis to spinal injury--is detailed by Dr. Neil Riordan. The American medical indu...

By: TheLipTV

Link:

Stem Cell Research & Therapy Explained - From MS to Spinal Injury - Video

Clinical Trials: Advanced Cell Technology - Stem Cell Therapy
Last month (October 2014) in The Lancet, Advanced Cell Technology (ACT) published their preliminary phase 1 clinical data for their Stem Cell therapy trials for Stargardt #39;s Macular Dystrophy...

By: Essceejulies

Go here to see the original:

Clinical Trials: Advanced Cell Technology - Stem Cell Therapy - Video

Dopamine-making neurons derived from human embryonic stem cells.

A rat model of Parkinson's disease has been successfully treated with neurons derived from human embryonic stem cells, according to a study led by Swedish scientists. Its a promising sign for scientists at The Scripps Research Institute and Scripps Health who hope to perform similar therapy on Parkinsons patients, using artificial embryonic stem cells.

In rats and people, neurons that make the neurotransmitter dopamine are essential for normal movement. The cells are destroyed in Parkinson's, leading to the difficulty in movement that characterizes the disease.

Researchers transplanted dopamine-producing cells grown from human embryonic stem cells into the brains of rats whose own dopamine-making neurons had been destroyed. The rats were immune-suppressed so they would not reject the cells. Within five months, the transplanted cells boosted dopamine production to normal levels, restoring normal movement in the rats.

The study was published Thursday in the journal Cell Stem Cell. The senior author was Malin Parmar of Lund University in Lund, Sweden.

The results support the Scripps approach of using the artificial embryonic stem cells, called induced pluripotent stem cells, said Jeanne Loring, who heads the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla. Loring is part of a group called Summit 4 Stem Cell that's raising funds to treat eight Parkinson's patients with their own IPS cells.

Particularly significant is the study's comparison of the effects of dopamine-making neurons derived from fetal cells to that of embryonic stem cells, Loring said by email.

"In the 1980s and 1990s, there were several clinical trials that showed that grafts of fetal brain containing the precursors of dopamine neurons could reverse the effects of Parkinson's disease in some patients," Loring said. "We, and the others developing stem cell therapies, based our plans on the results of those studies, but no one had ever directly compared fetal tissue and human pluripotent stem cell-derived dopamine neurons in an animal model of PD."

Induced pluripotent stem cells appear to have much the same capacity as human embryonic stem cells to generate different tissues and organs.

There has been uncertainty about how similar they are to each other, specifically whether the IPS process produces mutations. But recent studies have found the cell types are extremely similar, including a study also published in Cell Stem Cell on Thursday. That study compared IPS cells with embryonic stem cells produced by SCNT, or somatic cell nuclear transfer, the same process used to create Dolly the sheep.

View original post here:

Parkinson's stem cell therapy works in rats

(PRWEB UK) 9 November 2014

Every day stem cell treatments are in the news, often bringing the last hope for many patients with serious conditions that have defied traditional medicine.

BioEden's Group CEO Tony Veverka says, 'the increase in popularity in banking a persons own cells is as a result of two main things; 1. The likelihood of needing stem cell therapy is high, and 2. You need a stem cell match - your own cells are the perfect match'.

BioEden's tooth stem cell banking service is the only way you can access your own cells without the need for medical intervention. More and more parents are choosing to bank their children's stem cells as the baby tooth is shed naturally. However, stem cells can be banked from a healthy adult molar, that perhaps is being removed for orthodontic reasons.

Obtaining stem cells from other sources such as bone marrow is not only invasive but costly. Taking the decision to bank ones own cells is a sensible consideration, and costs from just 295.

Here is the original post:

BioEden the specialist tooth stem cell bank announce record sales up 45%

Stem Cell Therapy for Pets in Central Florida
http://www.NewmanVets.com Call your local Newman Veterinary Center for more information about stem cell therapy for pets. https://www.youtube.com/watch?v=7X23bmsy0Q8 feature=youtu.be.

By: Newman Veterinary Centers

Read the rest here:

Stem Cell Therapy for Pets in Central Florida - Video

Stem Cell Therapy for Multiple Sclerosis: Ron McGill
Ron McGill suffers from relapsing-remitting multiple sclerosis. He was started experiencing symptoms in 2009 but was not diagnosed with MS until January of 2013. He received several infusion...

By: http://www.cellmedicine.com

See more here:

Stem Cell Therapy for Multiple Sclerosis: Ron McGill - Video

Published November 07, 2014

A team of stem cell scientists has identified the biological mechanisms of Parkinsons disease and recreated a model of the disease in a dish.

Researchers at The New York Stem Cell Foundation (NYSCF) Research Institute studied a pair of identical twins one with Parkinsons and one without as well as another unrelated Parkinsons patient and four healthy control subjects to observe key characteristics of the disease. After comparing the individuals biological factors, they noticed differences in the patients neurons ability to produce dopamine. Dopamine production is deficient in Parkinsons disease.

"The unique scenario of identical twins, one with this disease and one without, allowed our scientists an unprecedented look into the mechanisms of Parkinson's disease," Susan L. Solomon, NYSCF chief executive officer, said in a news release. "Advanced stem cell research techniques allow us to push the boundaries of science and see what actually goes wrong at the cellular level, step by step during the disease process."

Parkinsons disease affects an estimated 500,000 people in the United States, according to the National Institutes of Health (NIH). The average age of onset is 60, and the risk of developing it increases with age. Symptoms of Parkinsons include tremor, shaking in the hands, arms, legs, jaw or head; impaired balance or postural instability; slowness of movement; and stiffness of the limbs and trunk.

There is currently no cure for Parkinsons.

While the disease is moderately hereditary, scientists have yet to fully understand the mechanisms of inheritance. The researchers note the DNA mutations that produce the enzyme glucocerebrosidase (GBA) have been linked to a five-fold increased risk of developing Parkinsons, but only 30 percent of people with this mutation have been shown to get the disease by age 80. This suggests that genetic and non-genetic factors cause Parkinsons. In studying the identical twins, scientists were able to analyze these mechanisms.

The scientists made induced pluripotent stem (iPS) cells from skin samples from both twins to generate a cellular model of Parkinsons in a dish, recreating the outstanding features of the disease specifically the dopamine and a-synuclein deficiency.

Scientists saw that the neurons from the twin affected by Parkinsons produced less dopamine and had higher levels of an enzyme called monomine oxidase B (MAO-B), as well as a poorer ability to connect with each other, compared to the twin that did not have the disease.

The findings suggest a possible therapy for Parkinsons: treating neurons with molecules that reduce the activity of MAO-B and GBA, while normalizing -synuclein and dopamine levels.

See the original post here:

Researchers create stem cell model of Parkinsons disease in a dish

David C P. Chen, MD., MHP - Stem Cell Therapy Q A1
David C P. Chen, MD., MHP - Stem Cell Therapy Q A1.

By: advanced anti aging center

Visit link:

David C P. Chen, MD., MHP - Stem Cell Therapy Q&A1 - Video

David C P. Chen, MD., MHP - Stem Cell Therapy Q A2

By: advanced anti aging center

Read more here:

David C P. Chen, MD., MHP - Stem Cell Therapy Q&A2 - Video

David C P. Chen, MD., MHP - Stem Cell Therapy Q A3

By: advanced anti aging center

More here:

David C P. Chen, MD., MHP - Stem Cell Therapy Q&A3 - Video

PUBLIC RELEASE DATE:

6-Nov-2014

Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation @nyscf

New York, NY (November 6, 2014) - A team of scientists led by The New York Stem Cell Foundation (NYSCF) Research Institute successfully created a human stem cell disease model of Parkinson's disease in a dish. Studying a pair of identical (monozygotic) twins, one affected and one unaffected with Parkinson's disease, another unrelated Parkinson's patient, and four healthy control subjects, the scientists were able to observe key features of the disease in the laboratory, specifically differences in the patients' neurons' ability to produce dopamine, the molecule that is deficient in Parkinson's disease. In addition, the scientists also identified a potential strategy for developing novel therapies for Parkinson's disease.

Attributed to a combination of genetic and nongenetic factors, Parkinson's disease has no completely effective therapy or cure. Parkinson's disease is moderately heritable, but the mechanisms of this inheritance are not well understood. While genetic forms of the disease exist, sporadic forms are far more common.

"The unique scenario of identical twins, one with this disease and one without, allowed our scientists an unprecedented look into the mechanisms of Parkinson's disease," said Susan L. Solomon, NYSCF Chief Executive Officer. "Advanced stem cell research techniques allow us to push the boundaries of science and see what actually goes wrong at the cellular level, step by step during the disease process."

DNA mutations resulting in the production of a specific enzyme called glucocerebrosidase (GBA) have been linked to a five-fold greater risk of developing Parkinson's disease; however, only 30% of individuals with this mutation have been shown to develop Parkinson's disease by the age of 80. This discordance suggests that multiple factors contribute to the development of Parkinson's disease, including both genetic and non-genetic factors. To date, there has been no appropriate model to identify and test multiple triggers leading to the onset of the disease.

In this study, published today in Cell Reports, a set of identical twins, both with a GBA mutation, provided a unique opportunity to evaluate and dissect the genetic and non-genetic contributions to the development of Parkinson's disease in one twin, and the lack of disease in the other. The scientists made induced pluripotent stem (iPS) cells from skin samples from both twins to generate a cellular model of Parkinson's in a dish, recapitulating key features of the disease, specifically the accumulation of -synuclein and dopamine deficiency.

Upon analyzing the cell models, the scientists found that the dopamine-producing neurons from both twins had reduced GBA enzymatic activity, elevated -synuclein protein levels, and a reduced capacity to synthesize and release dopamine. In comparison to his unaffected brother, the neurons generated from the affected twin produced less dopamine, had higher levels of an enzyme called monoamine oxidase B (MAO-B), and poor ability to connect with each other. Treating the neurons with molecules that lowered the activity of MAO-B together with overexpressed GBA normalized -synuclein and dopamine levels in the cell models. This suggests that a combination therapy for the affected twin may be possible by simultaneously targeting these two enzymes.

"The subject of Parkinson's disease discordant twins gave us an incredible opportunity to utilize stem cell models of disease in a dish to unlock some of the biological mechanisms of disease," said Dr. Scott Noggle, NYSCF Vice President, Stem Cell Research and The NYSCF - Charles Evans Senior Research Fellow for Alzheimer's Disease. "Working with these various different groups and scientists added to the depth and value of the research and we hope our findings will be applicable to other Parkinson's disease patients and other neurodegenerative disorders."

Link:

Scientists create Parkinson's disease in a dish